Psoriasis is a common condition where the skin gets red and scaly; psoriasis can cause itching, discomfort, and sometimes pain.
About this project
While it can begin at any age, psoriasis has 2 peaks of onset, the first at age 20 to 30 years and the second at age 50 to 60 years. It affects men and women equally but is more common in non-Hispanic whites. Some patients are more prone to developing psoriasis, especially if there is a family member with psoriasis. External factors such as infection, smoking, and certain medications can make psoriasis worse in some patients. Psoriasis is associated with a number of medical conditions.
- essays on the crime control model.
- Article summary?
- homeschool essay contest abortion;
- Current and potential new therapies for the treatment of psoriasis;
One-third of patients with psoriasis develop psoriatic arthritis, a progressive joint disease that can limit movement if untreated. Patients with severe psoriasis are also at higher risk than the general population for high blood pressure, diabetes, heart attacks, strokes, obesity, and depression. Different types of psoriasis exist, including plaque, guttate, erythrodermic, and pustular psoriasis. Among them, plaque psoriasis is the most common type. Plaque psoriasis appears as red, thick, scaly, raised-up areas on the skin that are itchy, painful, and can flake and bleed.
While plaque psoriasis can involve any part of the body, it commonly appears on the scalp, elbows, knees, trunk, and buttocks. Other types of psoriasis can look different and affect different areas of the body, such as nails, skin folds, or palms and soles. A patient with psoriatic arthritis often feels prolonged stiffness in the joints in the morning or during long periods of inactivity. Your doctor will ask you about your skin and joint symptoms, family history, and environmental exposures, such as recent infections, medications, or habits that may affect psoriasis.
Your doctor will examine your skin and may need to do a skin biopsy. Many treatment options exist for psoriasis. The treatment choice depends on the severity of psoriasis and whether you have psoriatic arthritis or other medical conditions. For mild or localized psoriasis, topical treatments, such as topical corticosteroids and topical vitamin D, are commonly used.
For moderate to severe psoriasis, 3 categories of treatments are considered—phototherapy, oral medications, and biologic medications. Phototherapy, or light therapy, uses specific ultraviolet light wavelengths to treat psoriasis.
[Full text] Secukinumab in the treatment of psoriasis: patient selection and persp | PTT
Both oral and biologic medications are systemic medications, which means that they affect not only the skin but also other parts of the body. Biologic medications reduce specific inflammation molecules that are abnormally elevated in psoriasis. Most biologic medications are delivered via injections into the fat layer of the skin and can result in substantial improvement of psoriasis.
No other conflicts are reported. Armstrong AW. JAMA Dermatol.
Clin Exp Dermatol ; Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial ESTEEM 2. Br J Dermatol ; Armstrong A, Levi E. Real-world clinical experience with apremilast in a large US retrospective cohort study of patients with moderate to severe plaque psoriasis.
Does biotin help with psoriasis?
J Drugs Dermatol ; Calcipotriol plus betamethasone dipropionate aerosol foam versus apremilast, methotrexate, acitretin, or fumaric acid esters for the treatment of plaque psoriasis: A matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study. J Am Acad Dermatol ; Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis.
Curr Rheumatol Rev Real-world experience with apremilast in treating psoriasis. J Cutan Med Surg ; Drug survival of apremilast in patients treated for psoriasis in a real-world setting. J Am Acad Dermatol ;e Longterm week results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol ; Ann Rheum Dis ; Rheumatology Oxford Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: A pooled analysis of the PALACE studies.
RMD Open ;4:e Early response to apremilast treatment in psoriatic arthritis: A real-life ultrasonographic follow-up study. Rheumatology Oxford ; Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
- case study on obesity and diabetes.
- college essay approaches.
- why i want to attend this school essay!
- sat essay scaled score.
J Dermatol ; Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study. Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting. J Eur Acad Dermatol Venereol ;e A pilot study of an oral phosphodiesterase inhibitor apremilast for atopic dermatitis in adults.
Arch Dermatol ; Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Rep Dermatol ; Arandomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Arch Dermatol Res Lack of efficacy of apremilast in 9 patients with severe alopecia areata. Improvement of alopecia areata with apremilast. Australas J Dermatol The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci ; Apremilast for treatment of recalcitrant aphthous stomatitis. Apremilast for Behcet's syndrome--a phase 2, placebo-controlled study. N Engl J Med ; Apremilast use in a case of cicatricial ectropion secondary to severe lamellar ichthyosis. Ophthalmic Plast Reconstr Surg ;ee7. Epidermolysis bullosa simplex generalized severe induces a Th17 response and is improved by Apremilast treatment.
Br J Dermatol Apremilast for treatment of recurrent erythema multiforme. Dermatol Online J ; Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. J Am Acad Dermatol Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients. An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series.
Three cases of palmoplantar pustulosis successfully treated with apremilast. J Dermatol Haebich G, Kalavala M. Successful treatment of refractory palmoplantar pustulosis with apremilast.
Clin Exp Dermatol Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. A case of severe pityriasis rubra pilaris with a dramatic response to apremilast. Eur J Dermatol ; Treatment of refractory pityriasis rubra pilaris with novel Phosphodiesterase 4 PDE4 inhibitor apremilast.
JAMA Dermatol ; Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. An oral phosphodiesterase inhibitor apremilast for inflammatory rosacea in adults: A pilot study. Treatment of severe hailey-hailey disease with apremilast. JAMA Dermatol Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
gohu-takarabune.com/policy/rastrear/tyqyv-localizar-un-celular.php Repigmentation of tenacious vitiligo on apremilast. Case Rep Dermatol Med ; Acase of anti-laminin gamma1 p pemphigoid with psoriasis vulgaris successfully treated with apremilast. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: week results of UNVEIL. Cutaneous hyperpigmentation induced by apremilast. Int J Dermatol ; Appearance of lentigines in psoriasis patients treated with apremilast. Purpura annularis telangiectodes of majocchi associated with the initiation and rechallenge of apremilast for psoriasis vulgaris. Norris MR, Bielory L.
Chronic tearing induced by apremilast. Ann Allergy Asthma Immunol Proximal renal tubular acidosis Fanconi Syndrome induced by apremilast: A case report. Am J Kidney Dis ;
Related psoriasis research paper
Copyright 2019 - All Right Reserved